WHO prequalifies heat-stable carbetocin for PPH prevention
Amsterdam, 15 July 2022 – Last year we added heat-stable carbetocin (HSC) to our Reproductive-, Maternal-, Newborn-, and Child-Health (RMNCH) portfolio. HSC is a uterotonic, that is more stable in warm and humid climates than its alternative oxytocin and is therefore better able to prevent post-partum haemorrhage (PPH) caused by post-partum uterine atony. Read the release article in this news item in our blog.
At IDA we have defined RMNCH as an underserved market, and by adding products to our portfolio that help reduce maternal mortality we are contributing to achieving Universal Health Coverage, one of our long-term goals, and to SDG target 3.1 (to reduce the global maternal mortality rate to under 70 maternal deaths per 100,000 live births by 2030).
We are happy to share the news that now WHO prequalified HSC (100 μg/mL solution for injection) earlier this month. This recognition is the first step in achieving registration in countries that exclusively rely on WHO’s prequalified products and compounds to facilitate a faster national approval and thus accelerate access to this life-saving commodity for the prevention of uterine haemorrhage due to post-partum uterine atony. Find more details on the prequalification here.